CytoPherx Raises $34M To Move Into U.S. Clinical Trials
CytoPherx Inc. announced it has completed a $34 million round of funding. The funds will be used to complete United States clinical trials and gain FDA approval to commercialize the CytoPherx anti-inflammatory therapy for acute kidney injury.
